Our Magazine
Brussels Morning Online Newspaper
Tuesday, January 19, 2021
No Result
View All Result
  • Home
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
  • Culture and Society
Brussels Morning Online Newspaper
  • Home
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
  • Culture and Society
Brussels Morning Online Newspaper
No Result
View All Result
Home Europe

BioNTech ups 2021 delivery plans to 2bn doses

Ivan Fischer by Ivan Fischer
12 January 2021
in Europe
BioNTech ups 2021 delivery plans to 2bn doses

Mainz, Rheinland-Pfalz, Germany-9. September 2020 Waving flags the Biontech logo at the Biontech building in Mainz

Share on FacebookShare on Twitter

Brussels (Brussels Morning) German pharmaceutical company BioNTech, which developed the first COVID-19 vaccine in the market in partnership with the US-based pharma giant Pfizer, announced it expects to produce some 2 billion doses of the vaccine, as it aims to boost its manufacturing, reported Reuters on Monday.

The company has previously planned for production of around 1 billion doses – sufficient for vaccinating 500 million people as two shots three weeks apart are required for full effect. However, company CEO and founder Ugur Sahin announced on Monday that the firm is hoping to double the figure of doses committed for this fiscal year.

New facilities

Sahin noted that the company currently has three manufacturing sites in the United States, and three in Europe operating or coming online soon, with the recent acquisition of a former Novartis site in Marburg, Germany, in September.

Another factor increasing the number of expected doses to be made available were the use of so-called low dead space syringes, which waste significantly less fluid per shot, making a standard vial worth six doses of the vaccine, instead of five.

Vaccine for children

At a presentation given during the J.P. Morgan Healthcare Conference, the company also shared plans to expand the group of viable recipients to include pregnant women and children, and noted it is working on a more stable variant of the vaccine, which will not pose logistical challenges with the requirement to be stored at extremely low temperatures.

The company has already delivered 32.9 million doses of its vaccine, with a total of 50 million doses produced by the end of 2020. This figure, the company claims, is in line with its plans, though additional deliveries had been held until specific orders are placed, in order to avoid excess storage time.

Tags: Main-SliderMainzRheinland-PfalzVaccine
Ivan Fischer

Ivan Fischer

Ivan is a Zagreb-based journalist with extensive experience in covering European and global politics, economy and emerging technology challenges. He is a foreign policy reporter for the leading Croatian daily Jutarnji list, as well as an alumnus of several journalism training programmes organised by Thomson Reuters Foundation and Robert Bosch Stiftung.

Latest post

Merkel’s‌ ‌CDU‌ ‌successor‌ ‌trails‌ ‌Bavaria’s‌ ‌premier‌ ‌as‌ ‌candidate‌ ‌for‌ ‌Chancellorship‌ ‌

Merkel’s‌ ‌CDU‌ ‌successor‌ ‌trails‌ ‌Bavaria’s‌ ‌premier‌ ‌as‌ ‌candidate‌ ‌for‌ ‌Chancellorship‌ ‌

7 mins ago
EU-funded project on new European building standards advances

EU-funded project on new European building standards advances

1 hour ago

Most Read

  • Italy’s cannabis industry could rival the legal market in the US

    Italy’s cannabis industry could rival the legal market in the US

    0 shares
    Share 0 Tweet 0
  • Can Armenia and Azerbaijan win peace together?

    0 shares
    Share 0 Tweet 0
  • The West cannot meet Russia half way

    0 shares
    Share 0 Tweet 0
  • How Emiratis shape the European defense agenda

    0 shares
    Share 0 Tweet 0
  • How EU trade and investment deals can fight climate change

    0 shares
    Share 0 Tweet 0

Subscribe
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.